Teva launches generic nasal spray for opioid overdose

Teva  credit: Shutterstock

Teva today announced the launch of a first-to-market generic version of Narcan (naloxone hydrochloride nasal spray), in the US.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) today announced the launch of a first-to-market generic version of Narcan (naloxone hydrochloride nasal spray), in the US.

Teva said that aloxone hydrochloride nasal spray is a prescription medicine used for the treatment of opioid emergencies such as an overdose or a possible opioid overdose with signs of breathing problems and severe sleepiness, or not being able to respond.

With nearly 550 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market, and holds the leading position in first-to-file opportunities, with 100 pending first-to-files in the US Currently, 1 in 12 generic prescriptions dispensed in the US is filled with a Teva generic product.

Teva is currently facing legal proceedings throughout the US in cases alleging its involvement in the manufacture and distribution of highly addictive opioid painkillers.

Published by Globes, Israel business news - en.globes.co.il - on December 23, 2021.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2021.

Teva  credit: Shutterstock
Teva credit: Shutterstock
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018